VYGRVoyager Therapeutics, Inc.

Nasdaq voyagertherapeutics.com


$ 6.49 $ -0.14 (-2.11 %)    

Wednesday, 28-Aug-2024 15:59:55 EDT
QQQ $ 472.70 $ -0.01 (-0 %)
DIA $ 411.36 $ -1.55 (-0.38 %)
SPY $ 560.29 $ 0.11 (0.02 %)
TLT $ 97.55 $ 0.00 (0 %)
GLD $ 231.76 $ -1.64 (-0.7 %)
$ 6.49
$ 6.49 x 196
-- x --
-- - --
$ 6.06 - $ 11.72
330,354
na
353.92M
$ 1.27
$ 39.22
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2024 06-30-2024 10-Q
2 05-13-2024 03-31-2024 10-Q
3 02-28-2024 12-31-2023 10-K
4 11-06-2023 09-30-2023 10-Q
5 08-03-2023 06-30-2023 10-Q
6 05-09-2023 03-31-2023 10-Q
7 03-07-2023 12-31-2022 10-K
8 11-08-2022 09-30-2022 10-Q
9 08-04-2022 06-30-2022 10-Q
10 05-04-2022 03-31-2022 10-Q
11 03-08-2022 12-31-2021 10-K
12 11-02-2021 09-30-2021 10-Q
13 08-09-2021 06-30-2021 10-Q
14 05-10-2021 03-31-2021 10-Q
15 02-25-2021 12-31-2020 10-K
16 11-09-2020 09-30-2020 10-Q
17 08-10-2020 06-30-2020 10-Q
18 05-06-2020 03-31-2020 10-Q
19 03-03-2020 12-31-2019 10-K
20 11-06-2019 09-30-2019 10-Q
21 08-09-2019 06-30-2019 10-Q
22 05-07-2019 03-31-2019 10-Q
23 02-26-2019 12-31-2018 10-K
24 11-07-2018 09-30-2018 10-Q
25 08-07-2018 06-30-2018 10-Q
26 05-10-2018 03-31-2018 10-Q
27 03-14-2018 12-31-2017 10-K
28 11-02-2017 09-30-2017 10-Q
29 08-08-2017 06-30-2017 10-Q
30 05-09-2017 03-31-2017 10-Q
31 03-15-2017 12-31-2016 10-K
32 11-10-2016 09-30-2016 10-Q
33 08-11-2016 06-30-2016 10-Q
34 05-12-2016 03-31-2016 10-Q
35 03-17-2016 12-31-2015 10-K
36 12-17-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-voyager-therapeutics-maintains-30-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Voyager Therapeutics (NASDAQ:VYGR) with a Buy and maintains $30 ...

 wedbush-maintains-neutral-on-voyager-therapeutics-lowers-price-target-to-7

Wedbush analyst Laura Chico maintains Voyager Therapeutics (NASDAQ:VYGR) with a Neutral and lowers the price target from $8 ...

 voyager-therapeutics-q2-2024-gaap-eps-018-beats-043-estimate-sales-29578m-beat-9461m-estimate

Voyager Therapeutics (NASDAQ:VYGR) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of ...

 hc-wainwright--co-reiterates-buy-on-voyager-therapeutics-maintains-30-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Voyager Therapeutics (NASDAQ:VYGR) with a Buy and maintains $30 ...

 voyager-therapeutics-taps-nathan-jorgensen-of-vor-bio-as-cfo-effective-july-8

 Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announc...

 hc-wainwright--co-reiterates-buy-on-voyager-therapeutics-maintains-30-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Voyager Therapeutics (NASDAQ:VYGR) with a Buy and maintains $30 ...

 oppenheimer-maintains-outperform-on-voyager-therapeutics-maintains-18-price-target

Oppenheimer analyst Jay Olson maintains Voyager Therapeutics (NASDAQ:VYGR) with a Outperform and maintains $18 price target.

 wedbush-maintains-neutral-on-voyager-therapeutics-lowers-price-target-to-8

Wedbush analyst Laura Chico maintains Voyager Therapeutics (NASDAQ:VYGR) with a Neutral and lowers the price target from $10...

 voyager-therapeutics-q1-2024-gaap-eps-020-beats-045-estimate-sales-19516m-beat-9415m-estimate

Voyager Therapeutics (NASDAQ:VYGR) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of ...

 voyager-therapeutics-presents-data-for-second-generation-tracer-generated-capsids-and-cns-gene-therapy-programs-advancing-toward-clinical-trials-at-the-asgct-annual-meeting

Translational potential of TRACER-derived AAV capsids demonstrated by data across multiple species (murine, porcine, multiple...

 guggenheim-initiates-coverage-on-voyager-therapeutics-with-buy-rating-announces-price-target-of-22

Guggenheim analyst Debjit Chattopadhyay initiates coverage on Voyager Therapeutics (NASDAQ:VYGR) with a Buy rating and annou...

 analyst-bullish-on-gene-therapy-focused-voyager-therapeutics-sees-best-in-class-potential-for-its-neurogenetic-medicine-platform

Unlock potential with Voyager Therapeutics as HC Wainwright initiates coverage highlights its TRACER capsid platform, promising...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION